GENEVA, July 9 -- NANJING ETERNAL INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD. filed a patent application (CN2025/121202) for “LOCALLY ACTING QUATERNARY AMMONIUM SALT-TYPE SPHINGOSINE-1-PHOSPHATE RECEPTOR SUBTYPE 1 AGONIST”. With publication no. WO/2026/144269, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: C07D 249/08
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....